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ABSTRACT 
        A sensitive and precise ultra high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) method 
has been developed and fully validated for therapeutic drug monitoring of everolimus in human whole blood. Sample preparation 
involved liquid-liquid extraction of everolimus and its deuterated internal standard (IS, everolimus-d4) from 100 µL blood sample 
using diethyl ether: ethyl acetate (30:70, v/v) solvent system under alkaline conditions. The chromatography was conducted on a 
COSMOSIL 2.5C18-MS-II (50 mm × 2.0 mm, 2.5 µm) analytical column. The analyte and  IS were eluted within 2.5 min under 
isocratic conditions using 10mM ammonium acetate, pH 6.00  adjusted with formic acid and acetonitrile (20:80, v/v). Multiple 
reaction monitoring was used for the quantitation of everolimus (m/z 975.5 → 908.5) and everolimus-d4 (m/z 979.6 → 912.6) in the 
positive ionization mode. The method was shown to be linear over the entire concentration range from 0.10-50.0 ng/mL. The 
recovery ranged from 90.9-94.8 % for everolimus and 91.4-95.6 % for everolimus-d4. The selectivity of the method is 
demonstrated in six different sources of blank human blood. The method is free from matrix effect as apparent from the 
post-column analyte infusion experiment, absolute and relative matrix effect results. The stability of everolimus in whole blood 
was thoroughly established under different storage conditions.    
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INTRODUCTION 
            Everolimus a macrocyclic lactone is a derivative of 
sirolimus having 2-hydroxyethyl chain at position 40 of the 
macrolide ring. It has potent antiproliferative and 
immunosuppressive effects with greater stability and solubility as 
well as more favourable pharmacokinetics [1]. Nevertheless, the 
immunosuppressive action of everolimus is similar to its parent 
drug sirolimus. Everolimus is a selective mammalian target of 
rapamycin (mTOR) inhibitor that specifically targets the mTOR 
signal transduction complex (mTORC1). It has shorter half-life 
(18-35 h across different treatment groups) than sirolimus and is 
thus administered twice a day. It is mainly bound to red blood cells 
(>75 %) and therefore blood matrix is recommended for 
pharmacokinetic studies. The oral bioavailability of everolimus is 
approximately 16 % and the time to reach peak plasma 
concentration is 0.5-1.0 h [2, 3].  Like sirolimus, it is metabolized 
by the CYP-450 enzyme system and is also a substrate for 
P-glycoprotein. Further, everolimus exhibits substantial intra- and 
inter-subject variation in its pharmacokinetics. Everolimus has a 
narrow therapeutic index and a variable bioavailability. The 
projected therapeutic range is 3.0–8.0 μg/L. At levels greater than 
3.0 μg/L, there has been less incidence of organ rejection, while at 
concentrations greater than 8.0 μg/L there are increased chances 
for toxicity [2-5]. Thus, sensitive and rugged methods are required 
for therapeutic drug monitoring (TDM) of everolimus. 
Several methods are presented in the literature to estimate 
everolimus from different human specimens like mouse plasma 
[6], human peripheral blood mononuclear cells [7], dried blood 
spots (DBS) [8, 9] and human whole blood [10-33] samples. The 
common techniques used for analysis includes immunoassay [3, 
23, 26], HPLC-UV [13, 23] and LC-MS/MS [8-12, 14-25, 27-32]. 
Due to cross reactions between the drug and their metabolites, 
immunoassay method are generally not preferred as they may 
cause overestimation of drug concentration with unacceptable 
bias. Thus, more selective LC-MS/MS methods are recommended 
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for TDM. Additionally, few other methods based on 
UPLC-MS/MS are presented for high-throughput applications [6, 
7, 33]. Hsieh et al. [6] described a ultra-performance hydrophilic 
interaction liquid chromatography (UPHILIC) for the 
determination of everolimus in the range of 10-5000 ng/mL in 
mouse plasma samples within 1.0 min. The plasma samples were 
prepared by protein precipitation with acetonitrile. Similarly, 
everolimus quantification (linear range 1.25-12.5 ng/mL) in 
peripheral blood mononuclear cells was also carried out by a 
UPLC-MS/MS method [7]. In the third UPLC-MS/MS method, 
five immunosuppressants were determined by improved sample 
preparation procedure using ZnSO4 (for haemolysis) and 
acetonitrile (for protein precipitation). The linear range 
established for everolimus was 1.0-28 ng/mL [33].  
 In the present work a sensitive, precise and a rugged 
UHPLC-MS/MS method has been developed using liquid-liquid 
extraction (LLE) of everolimus from whole blood samples. The 
method was thoroughly validated for selectivity, matrix effect, 
and stability. Under the optimized conditions, the sensitivity 
achieved was 0.10 ng/mL employing 100 µL human blood 
sample.   
EXPERIMENTAL 
Chemicals and materials 
Reference standards of everolimus (99.1 %) and 
everlimus-d4 (IS, 98.8 %) were obtained from Clearsynth Lab 
(Mumbai, India). HPLC grade acetonitrile and boric 
acid/potassium chloride/sodium hydroxide, pH 10.0 buffer was 
procured from Merck (Darmstadt, Germany). Formic acid and 
ammonium acetate was purchased from Spectrochem Pvt. Ltd. 
(Mumbai, India), and Sigma-Aldrich (St. Louis, MO, USA) 
respectively. Water used in the entire analysis was prepared from 
Milli-Q water purification system from Millipore (Bangalore, 
India). Lichrosep Sequence SPE Cartridge (30 mg, 1 mL) was 
purchased from Merck. Blank human blood was obtained from 
in-house clinical department and was stored at –20 C until use. 
Liquid chromatographic and mass spectrometric conditions 
 A Waters Acquity UPLC system (MA, USA) consisting of 
binary solvent manager, sample manager and column manager 
was used for setting the reverse-phase liquid chromatographic 
conditions. The analysis of everolimus and IS was performed on a 
COSMOSIL 2.5C18-MS-II (50 mm × 2.0 mm, 2.5 µm) analytical 
column maintained at 40°C in a column oven. For isocratic elution 
a mobile phase consisting of 10mM ammonium acetate, pH 6.00 
adjusted with formic acid and acetonitrile (20:80, v/v) was used. 
The flow rate of the mobile phase was kept at 0.400 mL/min and 
the sample manager temperature was maintained at 10 °C. 
 
Ionization and detection of everolimus and IS was carried 
out on a triple quadrupole mass spectrometer from Waters – Micro 
Mass Technologies (MA, USA), equipped with turbo ion spray 
interface and operating in positive ionization mode. Quantitation 
was performed using multiple reaction monitoring (MRM) mode 
to monitor precursor → product ion transitions of m/z 975.5 → 
908.5 for everolimus and m/z 979.6 → 912.6 for IS. A qualifying 
transition of m/z 975.5 → 926.6 and m/z 979.6 → 930.5 was also 
measured for the identification of analyte and IS respectively. For 
both the compounds, the optimized mass spectrometer parameters 
were as follows, capillary voltage 4.0 kV, desolvation temperature 
400 oC, desolvation gas flow 800 L/h, cone gas flow 50 L/h, and 
source temperature 100 oC. The compound specific parameters 
like cone voltage and collision energy were set at 27 V and 19 eV 
for everolimus and 30 V and 17 eV for IS respectively. 
Quadrupole 1 and 3 were maintained at unit mass resolution and 
the dwell time was set at 200 ms for both the drugs. Data 
collection, peak integration, and calculations were performed 
using Mass Lynx software version 4.1.  
Standard stock, calibration standards and quality control 
samples  
The standard stock solution of everolimus (1000 µg/mL) 
was prepared by dissolving requisite amount in methanol. 
Calibration standards (CSs) and quality control (QC) samples 
were prepared by spiking (2% of total blood volume) blank blood 
with stock solution. Calibration curve standards were made at 
0.100, 0.200, 0.600, 2.00, 4.00, 10.0, 25.0, 40.0, and 50.0 ng/mL 
concentrations respectively, while quality control samples were 
prepared at three levels, viz. 45.0 ng/mL (HQC, high quality 
control), 25.0/3.00 ng/mL (MQC-1/2, middle quality control 1/2), 
and 0.300 ng/mL (LQC, low quality control). Stock solution (0.2 
mg/mL) of the internal standard was prepared by dissolving 5.0 
mg of in 25.0 mL of methanol. Its working solution (100 ng/mL) 
was prepared by appropriate dilution of the stock solution in 
methanol. Standard stock and working solutions used were stored 
at 5 °C, while CSs and QC samples in plasma were kept at -70 °C 
until use. 
Sample extraction protocol 
Prior to analysis, all frozen subject samples, calibration 
standards and quality control samples were thawed and allowed to 
equilibrate at room temperature. To an aliquot of 100 µL of spiked 
blood sample, 50 µL of internal standard was added and 
vortex-mixed for about 15 sec. Further, 100 µL, boric 
acid/potassium chloride/sodium hydroxide pH 10.0 buffer was 
added and vortex for 1 min.   Extraction of analyte and IS was 
done with 2.5 mL of diethyl ether: ethyl acetate (30:70, v/v) on a 
rotary mixer (rotospin) for 10 min at 32 × g. Subsequently, 
centrifugation of the sample was done at 3204 × g for 5 min at 10 
°C.  Th  organic layer (2.0 mL) was separated and evaporated to 
dryness in a thermostatically controlled water-bath maintained at 
40°C under a gentle stream of nitrogen. The dried samples were 
reconstituted in 100µL of mobile phase and 5µL was used for 
injection in the chromatographic system. 
Method validation procedures 
The validation protocol and the acceptance criterion were 
essentially based on the USFDA guidelines [34] and similar to our 
previous work [35].  
System suitability was checked by injecting 6 successive 
injections of aqueous samples of everolimus (25 ng/mL) and IS 
(100 ng/mL) at the beginning of each batch. The precision (%CV) 
in the measurement of retention time it was in the range of 
0.11-0.15 %, and 0.45 to 1.19 for area response of everolimus and 
IS. The system performance was also verified with one processed 
blank sample, one upper limit of quantitation and one LLOQ 
along with the IS at the beginning and end of each batch. The S/N 
ratio was ≥ 40 for the analyte and IS. The auto sampler carry over 
for the analyte was checked by injecting the following sequence of 
injections: processed blank plasma, upper limit of quantitation 
(ULOQ) sample, processed blank plasma,  LLOQ sample, and 
processed blank plasma.  
The selectivity of the method was checked in six different 
batches/lots of blank blood which included 5 normal and 1 lipemic 
blood lots. The method linearity was evaluated from four linearity 
curves using least square weighted (1/x2) linear regression. 
Intra-batch accuracy and precision was assessed by analyzing six 
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replicates of LQC, MQC-1/2, and HQC samples from a single 
batch on the same day, while for inter-batch, five batches were 
analyzed on three consecutive days in a similar manner.  
Ion suppression/enhancement effects on the method 
sensitivity and selectivity was studied by the post column analyte 
infusion experiment. A standard solution containing everolimus 
(25 ng/mL) and IS (100 ng/mL) was infused post column via a ‘T’ 
connector into the mobile phase at 10µL/min employing an 
in-built infusion pump. Further, 5 µL aliquots of extracted control 
blood were then injected into the column and chromatogram was 
acquired for everolimus and IS.  
The extraction recovery of everolimus and matrix effect 
were determined at four QC levels in six replicates as reported 
previously [36]. Relative recovery or extraction recovery was 
calculated by comparing the mean area response of extracted 
samples (spiked before extraction) to that of unextracted samples 
(spiked after extraction) at each QC level for the analyte and IS. 
Absolute matrix effect was computed by comparing the mean area 
response of unextracted samples (spiked after extraction) with 
mean area of neat standard solutions. The relative matrix effect 
was also checked in six different batches/lots of blood at LQC and 
HQC levels. The precision and accuracy in the measurement of 
concentration was estimated at both these levels.  
The stability of everolimus and IS was examined in stock 
solutions and for the analyte in matrix by comparing the area 
response ratio (sirolimus/IS) of the stability samples with freshly 
prepared comparison samples.  Bench top stability at room 
temperature, wet extract (autosampler) stability at 5 °C, 
freeze-thaw and long-term stability (at -20°C and -70°C) in spiked 
blood samples were determined at LQC and HQC levels in six 
replicates.  
Dilution integrity was established from six replicates of 
standards prepared at 1/2 (45.0 ng/mL) and 1/10th (9.00 ng/mL) 
dilution, by spiking standard stock solution of everolimus (90.0 
ng/mL) in the screened blank blood. The precision and accuracy 
were evaluated by comparing the results against freshly prepared 
calibration curve standards. Method ruggedness was ascertained 
by analyzing two precision and accuracy batches. The first batch 
was analyzed by different analysts while the second batch was 
studied on two different columns.  
RESULTS AND DISCUSSION  
Method development 
As everolimus is predominantly present in red blood cells, 
its measurement in whole blood is required for TDM. The aim of 
this work was to develop a simple, sensitive and rugged protocol 
for everolimus for routine subject sample analysis. For selective 
extraction of immunosuppressants from whole blood sample 
preparation plays a crucial role. Several reports have highlighted 
the importance of protein precipitation with methanol/ ZnSO4 
followed by on-line SPE for rapid and reproducible results [12, 16, 
21, 22, 27]. Few other methods have optimized sample 
preparation with methanol-acetonitrile [17], followed by on-line 
SPE [19]. In the present work an attempt was made to use 
liquid-liquid extraction of everolimus without the need for on-line 
SPE as it has very low water solubility and a high log P value of 
5.01. Many trials were undertaken with different organic diluents 
like methyl tert-butyl ether, diethyl ether, dichloromethane, ethyl 
acetate and their combinations in different proportions (50:50, 
60:40, 70:30 and 80:20, v/v) at different pH (8.0, 9.0 and 10.0). 
The best extraction solvent system for quantitative and precise 
recovery of everolimus and everolimus-d4 was diethyl ether-ethyl 
acetate (30:70, v/v) at pH 10±0.1.  
To maximize the desired sensitivity and selectivity, 
electrospray ionization (+ESI) source was used to obtain good 
linearity in the regression curves. As reported by several authors 
[17, 21, 28, 33], protonated precursor ions [M+H]+ were not 
observed in the Q1 full scan mass spectra as it has less affinity for 
protons in the positive ionization mode. In the negative ionization 
mode the deprotonated ions were observed but the intensity was 
too low to achieve the desired sensitivity of 0.10ng/mL. The 
formation of sodium [M+Na]+ and ammonium ion [M+NH4]+ 
adducts were observed  in the positive ionization mode for 
everolimus and its deuterated analog. However, higher sensitivity 
was found for [M+NH4]+ compared to [M+Na]+ adduct as 
precursor ions using multiple reaction monitoring and hence was 
selected in the present work. The Q1 mass spectra for everolimus 
and IS showed peaks at m/z 975.5 and 979.6 respectively 
corresponding to the ammonium ion adducts. The most abundant 
product ions obtained in the Q3 scan were at m/z 908.5 and 912.6 
for everolimus and IS respectively, which were due to neutral loss 
of H2O, NH3 and CH3OH (Figure 1). To check the identity of the 
analyte and IS, a qualifying transition of m/z 975.5 → 926.6 and 
m/z 979.6 → 930.5 respectively was also monitored. A dwell time 
of 200 ms provided adequate number of data points for 
quantitation.   
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Figure 1 Product ion mass spectra of (A) everolimus (m/z 975.5 → 908.5, scan range 300-1000 amu) and (B) everolimus-d4 ( IS, m/z 
979.6 → 912.6, scan range 300-1000 amu) in the positive ionization mode.  
Several analytical columns have been tried for rapid 
chromatographic analysis of different immunosuppressants. 
Recently, Tszyrsznic et al. [33] developed a rapid and robust ultra 
performance liquid chromatography tandem mass spectrometry 
(UPLC/MS/MS) method for the quantification of four 
immunosuppressants in whole blood including everolimus on 
Waters UPLC BEH C18 column within 3.0 min. In the present 
work, two analytical columns namely BEH C18 (50 mm × 2.1mm, 
1.7µm) and COSMOSIL 2.5C18-MS-II (50 mm × 2.0 mm, 2.5 
µm) were tried to achieve symmetric peaks shapes, adequate 
retention and short run time under isocratic conditions. Several 
aqueous buffer-organic diluent combinations were tried using 
acetonitrile and methanol. Different buffer solutions having pH 
ranging from 4.0-9.0 were tested. The best elution conditions were 
optimized on COSMOSIL 2.5C18-MS-II column which provided 
better separation and shorter elution time compared to BEH C18 
column. By maintaining a flow rate of 0.400 mL/min, everolimus 
and IS was eluted at 1.97 and 1.96 min respectively. The choice of 
internal standard is critical in mass spectrometric analyses; use of 
general internal standards can cause errors in measurements due to 
ionization process different from that of the analyte [28]. Thus, 
deuterated internal standard was used which shares close chemical 
properties with the parent compound and had similar retention 
time. This can adequately compensate for any possible matrix 
effect and also for true recovery. The chromatograms in Figure 2 
of six extracted blank blood samples and everolimus at 0.10 
ng/mL concentrations, display the selectivity of the method. There 
were no peaks corresponding to the endogenous components at 
the retention time of everolimus.  A summary of salient features of 
liquid chromatographic methods with mass spectrometry 
detection for determination of everolimus in human whole blood 
is presented in Table 1. 
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Figure 2 Chromatograms showing selectivity of the method with six extracted blank blood samples, (A-E) K2EDTA and (F) lipemic and 
everolimus at lower limit of quantitation (0.10 ng/mL). 
Table 1 Comparison of salient features of the present method with selected liquid chromatography-mass spectrometric procedures for 
everolimus in human whole blood 
Extraction procedure Sample 
volume  
(µL) 
Linear range 
(ng/mL) 
Retention time 
(min); run time 
(min)  
Ref.  
PP with methanol/ZnSO4 followed by on-line 
SPE 
100  1.0-50  2.03; 2.50  12 
PP with methanol/ZnSO4 followed by on-line 
SPE 
250  2.5-30 7.00; 12.00   16 
PP with methanol-acetonitrile  200 2.5-50 
 
1.90; 2.60  17 
PP with methanol-acetonitrile followed by 
on-line SPE 
200  2.2-43.7 2.39; 6.00  19 
PP with methanol/ZnSO4 followed by on-line 
SPE  
100  1.2-48  
  
0.50; 1.00  21 
PP with methanol/ZnSO4 followed by on-line 
SPE 
50 2.3-24.6 2.67; 3.5 22 
PP with methanol/ZnSO4 followed by on-line 
SPE 
100 1.2-44.9 2.05; 2.80 27 
PP with ZnSO4 followed by on-line SPE 50 0.5-40.8 2.10; 2.40 28 
PP with methanol/ZnSO4 100 1.0-28 1.95; 2.50 33 
LLE with diethyl ether-ethyl acetate  100   0.10-50  1.97; 2.50  PW  
PP: protein precipitation; LLE: liquid-liquid extraction; SPE: solid phase extraction 
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To ascertain the interference of co-eluting matrix components, 
post-column infusion method was employed. The results shown in 
Figure 3 shows major ion suppression in the time frame of 1.25 to 
1.70 min, however, it did not interference in the quantitation of 
everolimus which eluted at 1.97 min. A similar observation was 
also reported by Buckwald and co-workers [28]. 
 
 
 
Figure 3 Chromatograms of three blank blood samples during 
post-column infusion of everolimus (3.00 ng/mL). 
Assay validation results 
 Autosampler carryover study was performed for each 
analytical run to ensure that it does not affect the accuracy and the 
precision of the proposed method. There was negligible carryover 
in any of the runs with no enhancement in the response for analyte 
or IS in double blank after subsequent injection of highest 
calibration standard at the retention time of everolimus and IS 
respectively as shown in Figure 4.  
The calibration curves were linear over the concentration 
range of 0.10–50.0ng/mL. A straight-line fit was made through the 
data points by least square regression analysis and a constant 
proportionality was observed. The mean and standard deviation 
value for slope, intercept and correlation coefficient (r2) is shown 
in Table 2. The accuracy and precision (%CV) observed for the 
calibration curve standards ranged from 89.3 to 99.8 % and 0.75 to 
6.26 % respectively. The signal to noise ratio (S/N) at the LLOQ 
concentration (0.10ng/mL) was ≥ 40.  
 
Figure 4 MRM chromatograms for carry over test of everolimus (m/z 975.5 → 908.5) and everolimus-d4 (IS, m/z 979.6 → 912.6) in (A) 
double blank blood (without analyte and IS), (B) everolimus (at ULOQ, 50.0 ng/mL) and IS (C) double blank blood (without analyte and 
IS) and (D) everolimus (at LLOQ, 0.10 ng/mL) and IS. 
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Table 2 Summary of back calculated concentrations for calibration curve standards of everolimus in human whole 
 
 
 
 ID No. 
CS-1 CS -2 CS -3 CS -4 CS -5 CS -6 CS -7 CS -8 CS -9 
 
 
 
Regression Parameters Nominal concentration (ng/mL) 
 
 
  
 
50.0 40.0 25.0 10.0 4.00 2.00 0.600 0.200 0.100 
 
Slope Intercept r2 
   1 49.2 39.0 23.8 9.72 3.59 2.16 0.602 0.194 0.089 
 
0.000823 0.010814 0.9993 
   2 46.8 38.6 23.5 8.95 3.65 1.86 0.576 0.189  0.087 
 
0.000920 -0.000855 0.9999 
   3 50.2 39.8 23.8 8.86 3.55 2.01 0.582 0.187 0.093 
 
0.000874  0.007498 0.9988 
   4 48.1 37.9 23.5 9.22 3.51 1.97 0.575 0.194 0.095 
 
0.000867 0.006661 0.9999 
Mean 48.6 38.8 23.7 9.19 3.57 1.99 0.584 0.191 0.091 
 
0.000871 0.006029 0.9995 
S.D. 1.46 0.76 0.18 0.38 0.06 0.16 0.013 0.004 0.004 
 
0.000040 0.004927 0.0006 
CV (%) 3.01 1.97 0.75 4.18 1.74 6.26 2.23 2.09 4.40 
 
 
Nominal 
(%) 
97.1 97.1 94.7 91.8 89.3 99.8 97.3 95.5 91.0 
 
The intra-batch precision (% CV) ranged from 1.27 to 8.25 % and the accuracy was within 95.78 to 102.8 %.  For the inter-batch 
experiments, the precision varied from 3.37 to 6.06 % and the accuracy was within 97-102 % (Table 3).  
 
 
 
 
Table 3 Intra-batch and inter-batch precision and accuracy for everolimus in human whole blood 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        CV: coefficient of variation 
 
The extraction recovery and absolute matrix effect results for everolimus and IS at different QC levels are presented in Table 4. The 
extraction recovery across QC levels for sirolimus and IS ranged from 90.9-94.8 % and 91.4-95.6 % respectively. The absolute matrix 
effect for everolimus varied from 98.6-102.3 %. 
  
 
Table 4 Matrix effect and recovery of everolimus and IS from human whole blood (n = 6) 
QC level Intra-batch (n = 6; single batch) Inter-batch (n = 30; 6 from each batch) 
Nominal 
concentration 
(ng/mL) 
Mean conc. 
found (ng/mL) 
CV (%) Accuracy (%) Mean conc. 
found for 5 
batches (ng/mL) 
CV (%) Accuracy (%) 
HQC (45.0) 43.11 1.27 95.78 44.07 4.48 97.93 
MQC-1 (25.0) 25.07 1.36 100.3 24.56 5.26 98.24 
MQC-2 (3.00) 3.084 3.79 102.8 3.042 5.42 101.4 
LQC (0.300) 0.297 3.70 99.00 0.296 3.37 98.67 
LLOQ (0.100) 0.097 8.25 97.00 0.099 6.06 99.00 
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CV: coefficient of variation; †values in parenthèses are for everolimus- d4 
A more specific method to evaluate matrix effect, expressed as relative matrix in different blood lots/batches showed % CV values of 
4.73 and 6.14 at LQC and HQC levels respectively as shown in Table 5.  
Table 5 Relative matrix effect for everolimus in six different lots of human whole blood 
 
            
 
Blood lots 
Observed concentration (ng/mL) 
 
LQC  (0.300 ng/mL) HQC  (45.0 ng/mL) 
 
1. K2EDTA 0.289 0.280 0.306 40.35 46.85 43.87 
2. K2EDTA 0.323 0.278 0.309 45.91 42.89 43.94 
3. K2EDTA 0.311 0.276 0.316 47.35 43.73 41.47 
4. K2EDTA 0.294 0.292 0.296 40.37 39.90 38.84 
5. K2EDTA 0.298 0.291 0.297 45.16 42.12 43.67 
6. Lipemic 0.273 0.306 0.285 43.62 40.99 47.86 
Mean  0.296 43.27 
SD 0.014 2.659 
CV (%) 4.73 6.14 
Accuracy (%) 98.67 96.16 
 
The stability results for everolimus in human whole blood under different storage conditions are shown in Table 6.  Stock solutions of 
analyte and IS kept for short-term stability remained unchanged up to 11 h, while the long term stability of stock solutions under 
refrigerated temperature below 8°C was established for a minimum of 45 days. Everolimus samples in control human blood for bench 
top stability were stable for at least 8h at 25°C and for minimum of five freeze and thaw cycles at –20 °C and –70 °C. Spiked blood 
samples stored at these two temperatures for long term stability were found stable for a minimum period of 93 days. Autosampler 
stability (wet extract) of the spiked QC samples maintained at 5 °C was determined up to 42 h without significant drug loss.  
 
Table 6 Stability of everolimus under different conditions in human whole blood (n = 6) 
Storage condition Nominal 
conc.  
(ng/mL)  
Mean, stability  
samples + SD 
Change (%) * 
Bench top stability at room temperature; 8 h 
HQC 45.00 44.40 ± 3.21  -1.33 
LQC 0.300 0.294 ± 0.014  -2.00 
Wet extract stability at 5 °C; 42 h 
HQC 45.00 41.57 ± 1.39  -7.62 
LQC 0.300 0.309 ± 0.037   3.00 
Freeze & thaw stability; 5 cycles, -20°C 
HQC 45.00 45.20 ± 3.27  0.44 
LQC 0.300 0.296 ± 0.017 -1.33 
 Mean area response of everolimus 
 
 
Absolute  
matrix 
effect†  
[B/A × 100] 
 
 
Relative recovery† 
[C/B × 100]  
QC 
level 
In mobile phase, A 
(CV, %) 
In post-extraction 
spiked sample, B (CV, 
%) 
In pre- extraction 
spiked sample, C 
(CV, %) 
HQC 1870470 (4.1) 
 
1867020 (1.5) 
 
1771250 (2.4) 
 
99.8 (97.3) 
 
94.8 (92.3) 
 MQC-
 
1059995 (4.8) 
 
1070970 (4.4) 
 
982480 (2.2) 
 
101.0 (98.6) 
 
91.7 (93.1) 
 MQC-
2 
121734 (0.9) 
 
120136 (5.1) 
 
109286 (2.7) 
 
98.6 (97.5) 
 
90.9 (91.4) 
 LQC 12194 (0.7) 
 
12477 (3.2) 
 
11751 (2.2) 
 
102.3 (99.8) 
 
94.2 (95.6) 
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Freeze & thaw stability; 5 Cycles, -70°C 
HQC 45.00 46.42 ± 1.83  3.16 
LQC 0.300 0.292 ± 0.007 -2.67 
Long term matrix stability in matrix; 93 days, -20°C 
HQC 45.00 43.23 ± 1.40 -3.93 
LQC 0.300 0.284 ± 0.005 -5.33 
Long term matrix stability in matrix; 93 days, -70°C 
HQC 45.00 45.51 ± 2.47  1.13 
LQC 0.300 0.312 ± 0.014  4.00 
100
samples comparisonMean 
samples comparisonMean –  samplesstability Mean  (%)  Change* ×=
 
 
The dilution test was performed to authenticate the method reliability for analyzing analyte concentration above the ULOQ 
concentration which may be encountered during subject sample analysis. The precision for dilution integrity of 1/2 and 1/10th dilution 
were 2.86 and 1.64 %, while the accuracy results were 97.62 and 96.22 % respectively, which is within the acceptance criteria for 
precision (15 % CV) and 85 to 115 % for accuracy (Table 7). Method ruggedness was evaluated using re-injection of analyzed samples 
on two different columns of the same make and also with different analysts. The precision (% CV) and accuracy values for two different 
columns ranged from 4.12 to 6.43 % and 94.3 to 98.1 % respectively at all four quality control levels.  For the experiment with different 
analysts, the results for precision and accuracy were within 3.45-5.78 % and 97.5-101.3 % respectively. 
 
Table 7 Dilution integrity experiment for everolimus at two dilutions 
 Observed concentration (ng/mL) 
 Dilution Factor: 2 Dilution Factor: 10 
Standard solution prepared in 
screened blank blood (90.0 
ng/mL) 
43.85 8.72 
45.64 8.85 
42.43 8.53 
43.62 8.79 
45.18 8.57 
42.90 8.52 
Mean 43.93 8.66 
Standard deviation 1.25 0.14 
Coefficient of variation (%) 2.86 1.64 
Accuracy (%) 97.62 96.22 
 
 `
CONCLUSIONS 
A highly sensitive method has been proposed for therapeutic drug 
monitoring of everolimus in human whole blood. The method 
presents a new liquid-liquid extraction procedure for quantitative 
and precise recovery of everolimus from blood samples. With a 
turnaround time of 2.5 min, the method can be readily applied to a 
clinical setting where large numbers of samples are to be 
analyzed. Moreover, the sensitivity of 0.10 ng/mL achieved is the 
highest compared to all other methods developed for everolimus 
in human specimens. Further, the method has shown to be 
practically free from matrix interference and the stability of 
everolimus is extensively proved under different storage 
conditions.  
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